Latest Market Expansion News

Ava Risk Group has appointed Bryant Henson as CEO to spearhead its next growth phase, with a sharp focus on expanding its footprint in the United States and strengthening commercial execution worldwide.

IMEXHS Limited posted a 21% revenue increase in Q2 FY26, driven by a landmark public tender in Mexico deploying its AI-powered Aquila+ radiology platform. The company’s proprietary AI agents are now operational in live environments, supporting its strategy to own the full radiology workflow.

Decidr AI Industries accelerated its commercial growth with a 71% jump in annualised exit-rate revenue to $13.6 million and bolstered its cash position to $23.4 million following a $14.2 million equity raise.

Orbital Corporation broadened its international footprint with new UAV propulsion orders across the US, India, and Middle East, while advancing its Power by the Hour service to underpin recurring revenue streams.

OncoSil Medical reported a 53% increase in unit sales and advanced key regulatory approvals, including FDA final review and TGA listing, positioning it for growth in pancreatic cancer treatment.

PainChek lifted implemented ARR by 5.9% to $4.46 million and secured its first US commercial contracts under a major Sabra REIT agreement, boosting customer receipts 27% in the June quarter.

De.mem Limited posted its second highest quarterly cash receipts of approximately $9.6 million for June 2026, marking 29 consecutive quarters of growth and positive operating cash flow of $424k. The company’s strong half-year performance is underpinned by recurring revenues, a robust Western Australian business, and record results from its German subsidiary.

Nodestream has advanced its defence strategy with key leadership hires, a $6.5 million capital raise, and fresh product launches, while expanding its footprint in the US and European markets.

Biome Australia capped FY26 with record $23.9 million sales and its flagship probiotic topping Australian pharmacy charts. The company signed an onshore manufacturing deal and expanded its proprietary probiotic clinical trial internationally.

RLF AgTech posted a seasonally strong June quarter with $7.1 million in cash receipts, driven by record pre-season payments in China and tight cost control that brought operating cash flow close to breakeven.

The Calmer Co International Ltd is raising up to $3.5 million through a 1-for-1 renounceable entitlement offer priced at $0.001 per share, including free attaching options exercisable at $0.002. The capital will fund debt repayment, inventory expansion, marketing, and product launches.

Lumos Diagnostics reported a 6% revenue increase to US$13.2 million for FY26, driven by an 875% surge in FebriDx® sales following a pivotal CLIA waiver. The company expanded U.S. adoption to 170+ healthcare sites and secured milestone payments exceeding US$6 million.